Table 2 Clinical characteristics of patients according to PLR
Variable | PLR ≤148 (N = 74) | PLR > 148 (N = 63) | P value |
|---|---|---|---|
Age, yr | 64 (58, 73) | 64 (54, 69) | 0.247 |
Sex | Â | Â | 1.000 |
 Male | 45 (60.8%) | 38 (60.3%) |  |
 Female | 29 (39.2%) | 25 (39.7%) |  |
BMI | 23.7 (22.2, 25.7) | 23.0 (22.0, 24.5) | 0.119 |
ECOG Performance status | Â | Â | 1.000 |
 0 | 35 (47.3%) | 29 (46.0%) |  |
  ≥ 1 | 39 (52.7%) | 34 (54.0%) |  |
Liver cirrhosis | 10 (13.5%) | 5 (7.9%) | 0.443 |
Diabetes mellitus | 15 (20.3%) | 10 (15.9%) | 0.658 |
Charlson Commorbidity Index | Â | Â | 0.595 |
 0 | 45 (60.8%) | 42 (66.7%) |  |
  ≥ 1 | 29 (39.2%) | 21 (33.3%) |  |
Biliary drainage | 6 (8.1%) | 9 (14.3%) | 0.379 |
Tumor size, cm | 7.2 (5.4, 10.0) | 7.0 (4.5, 9.6) | 0.246 |
Major vascular invasion | 53 (71.6%) | 36 (57.1%) | 0.112 |
Hilar invasion | 9 (12.2%) | 7 (11.1%) | 1.000 |
Liver metastasis | 27 (36.5%) | 28 (44.4%) | 0.440 |
Extrahepatic organ metastasis | 38 (51.4%) | 37 (58.7%) | 0.489 |
Distant lymph node metastasis | 47 (63.5%) | 43 (68.3%) | 0.688 |
Number of metastatic sites | Â | Â | 0.090 |
 0 | 10 (13.5%) | 2 (3.2%) |  |
 1 | 27 (36.5%) | 23 (36.5%) |  |
  ≥ 2 | 37 (50.0%) | 38 (60.3%) |  |
Baseline laboratory findings | |||
 Neutrophil count, cells/μL | 5288 (3768, 6403) | 5792 (4663, 7231) | 0.063 |
 Lymphocyte count, cells/μL | 1935 (1547, 2271) | 1377 (1119, 1623) | < 0.001 |
 Monocyte count, cells/μL | 637 (509, 808) | 629 (506, 756) | 0.837 |
 Platelet count, 103 cells/μL | 199 (163, 255) | 261 (224, 303) | < 0.001 |
 Total bilirubin, mg/dL | 0.7 (0.6, 0.9) | 0.7 (0.5, 0.9) | 0.979 |
 ALP, IU/L | 129 (93, 225) | 164 (115, 259) | 0.074 |
 Albumin, g/dL | 4.0 (3.7, 4.2) | 3.8 (3.5, 4.1) | 0.030 |
 CA 19–9, U/mL | 652.5 (44.6, 4830.0) | 183.4 (16.1, 2955.0) | 0.211 |